Abiopharma

🔍 Doyle John Q (Executive)

Company: MARSH & MCLENNAN COMPANIES, INC. (MRSH)

Report Date: 2026-09-02

Detailed Transactions and Holdings:

• Acquired 16,656 shares of Common Stock at $73.195 per share (Direct)
  Date: 2026-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 133,467.02 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,656 shares of Common Stock at $188.51 per share (Direct)
  Date: 2026-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 116,811.02 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,656 shares of Stock Options (Right to Buy) at $73.195 per share (Derivative)
  Date: 2026-09-02 | Code: M | Expires: 2027-02-21 | equity_swap_involved: 0 | shares_owned_after: 16,656.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
• F2: These options were granted on February 22, 2017 and vested in four equal annual installments on February 22nd of 2018, 2019, 2020 and 2021.